Adam Leigh1, John W McEvoy2, Parveen Garg3, J Jeffrey Carr4, Veit Sandfort5, Elizabeth C Oelsner6, Matthew Budoff7, David Herrington1, Joseph Yeboah8. 1. Heart and Vascular Center of Excellence, Wake Forest University School of Medicine, Winston Salem, North Carolina. 2. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. 4. Departments of Cardiology and Radiology, Vanderbilt University School of Medicine, Nashville, Tennessee. 5. Clinical Center, National Institutes of Health, Bethesda, Maryland. 6. Departments of Medicine and Epidemiology, Columbia University, New York, New York. 7. Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles, Torrance California. 8. Heart and Vascular Center of Excellence, Wake Forest University School of Medicine, Winston Salem, North Carolina. Electronic address: jyeboah@wakehealth.edu.
Abstract
OBJECTIVES: This study assessed the utility of the pooled cohort equation (PCE) and/or coronary artery calcium (CAC) for atherosclerotic cardiovascular disease (ASCVD) risk assessment in smokers, especially those who were lung cancer screening eligible (LCSE). BACKGROUND: The U.S. Preventive Services Task Force recommended and the Centers for Medicare & Medicaid Services currently pays for annual screening for lung cancer with low-dose computed tomography scans in a specified group of cigarette smokers. CAC can be obtained from these low-dose scans. The incremental utility of CAC for ASCVD risk stratification remains unclear in this high-risk group. METHODS: Of 6,814 MESA (Multi-Ethnic Study of Atherosclerosis) participants, 3,356 (49.2% of total cohort) were smokers (2,476 former and 880 current), and 14.3% were LCSE. Kaplan-Meier, Cox proportional hazards, area under the curve, and net reclassification improvement (NRI) analyses were used to assess the association between PCE and/or CAC and incident ASCVD. Incident ASCVD was defined as coronary death, nonfatal myocardial infarction, or fatal or nonfatal stroke. RESULTS: Smokers had a mean age of 62.1 years, 43.5% were female, and all had a mean of 23.0 pack-years of smoking. The LCSE sample had a mean age of 65.3 years, 39.1% were female, and all had a mean of 56.7 pack-years of smoking. After a mean of 11.1 years of follow-up 13.4% of all smokers and 20.8% of LCSE smokers had ASCVD events; 6.7% of all smokers and 14.2% of LCSE smokers with CAC = 0 had an ASCVD event during the follow-up. One SD increase in the PCE 10-year risk was associated with a 68% increase risk for ASCVD events in all smokers (hazard ratio: 1.68; 95% confidence interval: 1.57 to 1.80) and a 22% increase in risk for ASCVD events in the LCSE smokers (hazard ratio: 1.22; 95% confidence interval: 1.00 to 1.47). CAC was associated with increased ASCVD risk in all smokers and in LCSE smokers in all the Cox models. The C-statistic of the PCE for ASCVD was higher in all smokers compared with LCSE smokers (0.693 vs. 0.545). CAC significantly improved the C-statistics of the PCE in all smokers but not in LCSE smokers. The event and nonevent net reclassification improvements for all smokers and LCSE smokers were 0.018 and -0.126 versus 0.16 and -0.196, respectively. CONCLUSIONS: In this well-characterized, multiethnic U.S. cohort, CAC was predictive of ASCVD in all smokers and in LCSE smokers but modestly improved discrimination over and beyond the PCE. However, 6.7% of all smokers and 14.2% of LCSE smokers with CAC = 0 had an ASCVD event during follow-up.
OBJECTIVES: This study assessed the utility of the pooled cohort equation (PCE) and/or coronary artery calcium (CAC) for atherosclerotic cardiovascular disease (ASCVD) risk assessment in smokers, especially those who were lung cancer screening eligible (LCSE). BACKGROUND: The U.S. Preventive Services Task Force recommended and the Centers for Medicare & Medicaid Services currently pays for annual screening for lung cancer with low-dose computed tomography scans in a specified group of cigarette smokers. CAC can be obtained from these low-dose scans. The incremental utility of CAC for ASCVD risk stratification remains unclear in this high-risk group. METHODS: Of 6,814 MESA (Multi-Ethnic Study of Atherosclerosis) participants, 3,356 (49.2% of total cohort) were smokers (2,476 former and 880 current), and 14.3% were LCSE. Kaplan-Meier, Cox proportional hazards, area under the curve, and net reclassification improvement (NRI) analyses were used to assess the association between PCE and/or CAC and incident ASCVD. Incident ASCVD was defined as coronary death, nonfatal myocardial infarction, or fatal or nonfatal stroke. RESULTS: Smokers had a mean age of 62.1 years, 43.5% were female, and all had a mean of 23.0 pack-years of smoking. The LCSE sample had a mean age of 65.3 years, 39.1% were female, and all had a mean of 56.7 pack-years of smoking. After a mean of 11.1 years of follow-up 13.4% of all smokers and 20.8% of LCSE smokers had ASCVD events; 6.7% of all smokers and 14.2% of LCSE smokers with CAC = 0 had an ASCVD event during the follow-up. One SD increase in the PCE 10-year risk was associated with a 68% increase risk for ASCVD events in all smokers (hazard ratio: 1.68; 95% confidence interval: 1.57 to 1.80) and a 22% increase in risk for ASCVD events in the LCSE smokers (hazard ratio: 1.22; 95% confidence interval: 1.00 to 1.47). CAC was associated with increased ASCVD risk in all smokers and in LCSE smokers in all the Cox models. The C-statistic of the PCE for ASCVD was higher in all smokers compared with LCSE smokers (0.693 vs. 0.545). CAC significantly improved the C-statistics of the PCE in all smokers but not in LCSE smokers. The event and nonevent net reclassification improvements for all smokers and LCSE smokers were 0.018 and -0.126 versus 0.16 and -0.196, respectively. CONCLUSIONS: In this well-characterized, multiethnic U.S. cohort, CAC was predictive of ASCVD in all smokers and in LCSE smokers but modestly improved discrimination over and beyond the PCE. However, 6.7% of all smokers and 14.2% of LCSE smokers with CAC = 0 had an ASCVD event during follow-up.
Authors: Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner Journal: Circulation Date: 2014-12-17 Impact factor: 29.690
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Joseph Shemesh; Claudia I Henschke; Dorith Shaham; Rowena Yip; Ali O Farooqi; Matthew D Cham; Dorothy I McCauley; Mildred Chen; James P Smith; Daniel M Libby; Mark W Pasmantier; David F Yankelevitz Journal: Radiology Date: 2010-09-09 Impact factor: 11.105
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Ivana Isgum; Mathias Prokop; Meindert Niemeijer; Max A Viergever; Bram van Ginneken Journal: IEEE Trans Med Imaging Date: 2012-09-03 Impact factor: 10.048
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: Timothy R Church; William C Black; Denise R Aberle; Christine D Berg; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; David S Gierada; Gordon C Jones; Irene Mahon; Pamela M Marcus; JoRean D Sicks; Amanda Jain; Sarah Baum Journal: N Engl J Med Date: 2013-05-23 Impact factor: 91.245
Authors: Seth S Martin; Michael J Blaha; Ron Blankstein; Arthur Agatston; Juan J Rivera; Salim S Virani; Pamela Ouyang; Steven R Jones; Roger S Blumenthal; Matthew J Budoff; Khurram Nasir Journal: Circulation Date: 2013-10-20 Impact factor: 29.690
Authors: Khurram Nasir; Marcio S Bittencourt; Michael J Blaha; Ron Blankstein; Arthur S Agatson; Juan J Rivera; Michael D Miedema; Michael D Miemdema; Christopher T Sibley; Leslee J Shaw; Roger S Blumenthal; Matthew J Budoff; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2015-10-13 Impact factor: 24.094
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Philip Greenland; Michael J Blaha; Matthew J Budoff; Raimund Erbel; Karol E Watson Journal: J Am Coll Cardiol Date: 2018-07-24 Impact factor: 24.094
Authors: Gianluca Pontone; Alexia Rossi; Marco Guglielmo; Marc R Dweck; Oliver Gaemperli; Koen Nieman; Francesca Pugliese; Pal Maurovich-Horvat; Alessia Gimelli; Bernard Cosyns; Stephan Achenbach Journal: Eur Heart J Cardiovasc Imaging Date: 2022-02-22 Impact factor: 6.875
Authors: Omar Dzaye; Philipp Berning; Zeina A Dardari; Daniel S Berman; Matthew J Budoff; Michael D Miedema; Khurram Nasir; Alan Rozanski; John A Rumberger; Leslee J Shaw; Martin Bødtker Mortensen; Seamus P Whelton; Michael J Blaha Journal: Atherosclerosis Date: 2021-10-18 Impact factor: 5.162
Authors: Kyle Wang; Hayley E Malkin; Nicholas D Patchett; Kevin A Pearlstein; Hillary M Heiling; Sean D McCabe; Allison M Deal; Panayiotis Mavroidis; Mary Oakey; Jeffrey Fenoli; Carrie B Lee; J Larry Klein; Brian C Jensen; Thomas E Stinchcombe; Lawrence B Marks; Ashley A Weiner Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-19 Impact factor: 7.038
Authors: Tina D Tailor; Caroline Chiles; Joseph Yeboah; M Patricia Rivera; Betty C Tong; Fides R Schwartz; Thad Benefield; Lindsay M Lane; Ilona Stashko; Samantha M Thomas; Louise M Henderson Journal: J Am Coll Radiol Date: 2021-02-26 Impact factor: 6.240
Authors: Jared L Christensen; Esseim Sharma; Anastassia Y Gorvitovskaia; Jerome P Watts; Maen Assali; Jade Neverson; Wen-Chih Wu; Gaurav Choudhary; Alan R Morrison Journal: J Am Heart Assoc Date: 2019-01-08 Impact factor: 5.501
Authors: Mamta Ruparel; Samantha L Quaife; Jennifer L Dickson; Carolyn Horst; Stephen Burke; Magali Taylor; Asia Ahmed; Penny Shaw; May-Jan Soo; Arjun Nair; Anand Devaraj; Emma Louise O'Dowd; Angshu Bhowmik; Neal Navani; Karen Sennett; Stephen W Duffy; David R Baldwin; Reecha Sofat; Riyaz S Patel; Aroon Hingorani; Sam M Janes Journal: Thorax Date: 2019-09-26 Impact factor: 9.102
Authors: Cilie C van 't Klooster; Hendrik M Nathoe; J Hjortnaes; Michiel L Bots; Ivana Isgum; Nikolas Lessmann; Yolanda van der Graaf; Tim Leiner; Frank L J Visseren Journal: Int J Cardiol Heart Vasc Date: 2020-03-17